Hemostasis Today

February, 2026
February 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
232425262728  
Kanishk Kumar – Hemophilia A Pipeline 2025: New Therapies Changing Patient Care 
Oct 21, 2025, 06:12

Kanishk Kumar – Hemophilia A Pipeline 2025: New Therapies Changing Patient Care 

Kanishk Kumar, Digital Marketing Executive at DelveInsight Business Research LLP, posted on LinkedIn:

“Hemophilia A Pipeline 2025: New Therapies Changing Patient Care

The Hemophilia A treatment landscape is evolving fast in 2025. Researchers and companies are pushing forward gene therapies, long-acting factor replacements, and innovative prophylactic options, all aimed at improving patients’ quality of life and reducing the burden of frequent treatments.

Recent Highlights:

On 10 October 2025, Roche initiated a Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NXT007 in patients with severe or moderate Hemophilia A.

On 08 October 2025, BioMarin Pharmaceutical Inc. announced a Phase III study to assess the safety and effectiveness of valoctocogene roxaparvovec in combination with prophylactic corticosteroids in patients with severe Hemophilia A.

Key companies leading the way include Roche, Chugai Pharmaceutical Co., Ltd. , Shire , Pfizer , BioMarin Pharmaceutical Inc., Sinocelltech Ltd., Bayer, Ultragenyx , Spark Therapeutics, Inc., Octapharma, APCINTEX LIMITED , Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Expression Therapeutics, Inc., CSL and others.”

Kanishk Kumar - Hemophilia A Pipeline 2025: New Therapies Changing Patient Care 

See the full Hemophilia A Pipeline 2025 report and track the therapies shaping the future here.

Stay updated with Hemostasis Today.